A NEW ERA FOR NMIBC: How a decade of progress is reshaping the treatment landscape.

Detalles Bibliográficos
Publicado en:Urology Times Vol. 53; no. 1; pp. 16 - 19
Autor principal: Clarke, Hannah
Formato: pictorial Journal Article
Publicado: MJH Life Sciences Jan2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=182580679&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 182580679
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00939722
        URO
      jtl: Urology Times
      issn: 00939722
      maglogo: N
    pubinfo:
      dt: Jan2025
      vid: 53
      iid: 1
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        182580679
        182580679
        182580679
        182580679
      ppf: 16
      ppct: 3
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: A NEW ERA FOR NMIBC: How a decade of progress is reshaping the treatment landscape.
      aug:
        au: Clarke, Hannah
      sug:
        subj:
          Non-Muscle Invasive Bladder Neoplasms Drug Therapy
          BCG Vaccine Therapeutic Use
          Immunotherapy
          Chemotherapy, Adjuvant
          Valrubicin
          Antibodies, Monoclonal
          Drug Development
          Patient Selection
          Clinical Trials
          Treatment Outcomes
          Survival Rate
          Translational Medical Research
          Drug Approval
          Urologists
      pubtype: Academic Journal
      doctype:
        pictorial
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N